Potentially, STAT3 inhibition by itself might already reduce the inhibitory effect of the PD-1/PD-L1 axis, especially when tumor PD-L1 expression is regulated through oncogenic pathway activation often seen in HPV− HNSCC. The gene discussed is STAT3; the disease is neoplasm.